Co-Morbidities in psoriatic versus non-psoriatic patients

Houssien, Rana Omar Al; Sheikh, Afaf Al

doi:10.4103/jhs.jhs_89_17

Cited by 3 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, numerous studies have reported systemic changes, such as dyslipidemia, cytokines, and inflammatory and immunologic biomarker abnormalities [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27]. Some researchers suggest that psoriasis is a systemic disease rather than a local skin disease [6,7,17,[28][29][30][31][32][33][34][35].…”

Section: Introductionmentioning

confidence: 99%

Psoriasis is a systemic disease: A proposed approach for inflammation scale calculation

Alsamarai¹,

Alobaidii²

2021

Our Dermatol Online

View full text Add to dashboard Cite

Background: Psoriasis is a skin disease affecting 2.3% of the Iraqi population and begins as a local disease with subsequent systemic comorbidities. Aim: The aim was to clarify whether psoriasis is a local or systemic disease. Materials and Methods: A total of 211 subjects with psoriasis and 163 sex- and age-matched controls were included in the study. Serum adiponectin, interleukin-6, interleukin-8, interleukin-10 (IL-10), interleukin-23 (IL-23), interleukin-18 (IL-18), paraoxonase, lipoprotein (a), osteopontin, chemerin, tumor necrosis factor-a (TNF-a), high-sensitivity C- reactive protein (hs-CRP), bilirubin, D-dimer, and creatinine were determined using commercial kits. Results: There was no significant difference in the mean age and BMI between psoriasis and the control groups. However, there was significantly higher mean serum values of IL-6, IL-8, IL-10, IL-23, lipoprotein (a), chemerin, TNF-a, hs-CRP, osteopontin, D-dimer, troponin I, creatinine, bilirubin, and platelet counts in psoriatic patients than in the controls. Meanwhile, the serum mean values of adiponectin, paraoxonase, and cortisol were significantly lower in psoriasis subjects than in the controls. The mathematical model was proposed to clarify whether psoriasis is a systemic or local disease. The application of the model to our data of biomarkers indicated the presence of systemic inflammation in psoriasis. Conclusion: The present study finding suggests that psoriasis is a systemic disease rather than a local skin disease. However, there is a need for the application of the model in a large-scale study.

show abstract

Section: Introductionmentioning

confidence: 99%

Psoriasis is a systemic disease: A proposed approach for inflammation scale calculation

Alsamarai¹,

Alobaidii²

2021

Our Dermatol Online

View full text Add to dashboard Cite

show abstract

“…Previous studies indicated that psoriasis started as local skin disease and subsequently associated with systemic inflammatoryimmunologic and metabolic changes [7,8] . The systemic changes in patients with psoriasis were reported in studies conducted in Iraqi population [5,6,9,10] and worldwide [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25]. The data presented in the above studies that are from different global communities indicated that psoriasis co-morbidities development are not confined to specific race, developing or developed communities.…”

Section: Introductionmentioning

confidence: 83%

Psoriasis Beyond Local Skin Disease

2021

MLU

View full text Add to dashboard Cite

Background: Psoriasis is a skin disease that was associated with metabolic and clinical changes which suggest that psoriasis is a systemic rather than local disease.Aim: To illustrate whether psoriasis is local or systemic disease through analysis of some biomarkers. Materials andMethod: A 256 subjects with psoriasis and 221 sex and age matched controls were included in the study. Serum total cholesterol [TC], high density lipoprotein [HDL], Malondialdehyde [MDA], triglycerides [TG], and total antioxidant capacity [TCA] were determined using commercial kits.Results: There were no significant differences between psoriasis and control groups in regards to mean age and gender distribution, however, there was a significant difference [p<0.01] in BMI. Additionally, TC, TG, LDL and NHDL were significantly higher [P<0.001] in patients with psoriasis than in controls, while HDL was significantly lower in psoriasis than in controls. MDA mean serum level was significantly higher [P<0.001] lower while TCA value was significantly [P<0.001] lower in subjects with psoriasis as compared controls. Lipid profile rates and oxidation index were significantly higher in psoriasis than in controls, while the anti-oxidation index was significantly lower in psoriasis. Conclusion:These study findings suggest that psoriasis may be a systemic disease rather than local skin disease.

show abstract

“…Studies on the patterns of comorbidities seen with psoriasis have been explored in numerous countries on various races and ethnicities, but these patterns have only been slightly investigated in the Saudi population [ 2 , 10 , 12 , 13 ]. Due to the distinct nature of psoriasis types, classifications, and clinical presentations that separates it from other dermatological conditions, it is essential to investigate patterns of different comorbidities and diseases with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

“…Globally, several studies assessed the association between psoriasis and several different comorbidities. However, only a few studies were conducted in Riyadh, and no recent studies in the western region [ 2 , 10 , 13 ]. In consideration of that, this paper will be of much benefit in improving the standard of practice conducted in our center.…”

Section: Introductionmentioning

confidence: 99%

Patterns of Comorbidities in Psoriasis Patients: A Cross-Sectional Study

Alajmi

Alamoudi

Alabbasi

et al. 2021

Cureus

View full text Add to dashboard Cite

Background: Psoriasis is a chronic, inflammatory, and immune-mediated dermatological disease of unknown etiology with predominant involvement of the skin, nails, and joints. This study aimed to assess comorbidities patterns in psoriasis patients. Methods: This is a cross-sectional study conducted at King Abdulaziz Medical City (KAMC) in Jeddah, Saudi Arabia. Data were collected through a retrospective chart review of the electronic medical record system (Bestcare, Ezcaretech, Seoul, Korea) and by utilizing a structured data collection sheet. Results: A total of 128 confirmed psoriasis cases were included with a mean age of 44.2 ± 17.3. The sample had 45.7% females and 54.3% males. Nearly half the patients (46.1%) had no comorbidities, followed by those who had at least one comorbidity (24.2%) and those who had two or more comorbidities (29.7%). Most patients were classified as plaque psoriasis (57.0%), followed by those who had psoriatic arthritis (13.3%). There was no statistical significance between gender, body mass index (BMI), and smoking with the number of comorbidities (P= 0.422, P=0.361, P=0.772); 41.2% of psoriatic arthritis patients and all erythrodermic arthritis patients had two or more comorbidities, which is statistically significant at p -value <0.018. Conclusion: This study demonstrated the prevalence of different comorbidities associated with psoriasis patients; 41.2% of psoriatic arthritis patients and all erythrodermic arthritis patients had two or more comorbidities, which was statistically significant. This necessitates closer monitoring of different comorbidities a psoriasis patient might present with. Especially those who are diagnosed with psoriatic arthritis and erythrodermic arthritis.

show abstract

Co-Morbidities in psoriatic versus non-psoriatic patients

Cited by 3 publications

References 2 publications

Psoriasis is a systemic disease: A proposed approach for inflammation scale calculation

Psoriasis is a systemic disease: A proposed approach for inflammation scale calculation

Psoriasis Beyond Local Skin Disease

Patterns of Comorbidities in Psoriasis Patients: A Cross-Sectional Study

Contact Info

Product

Resources

About